Objective: To investigate the clinical efficacy of Erlong Zuoci Wan combined with Tongqi San in treatment of chronic secretory otitis media (CSOM) with syndrome of deficiency of liver and kidney and observe its effects on aquaporin (AQP)-1 and AQP-4 levels in serum. Method: One hundred and seventeen patients with chronic secretory otitis media in our hospital were randomly divided into control group (59 cases) and treatment group (58 cases) by referring to the random number table method. Patients in the control group were treated with cefetamet pivoxil hydrochloride dispersible tablets (500 mg/time

bid)

desloratadine citrate disodium tablets (1 tablet/time

qd) and xylometazoline nasal drops (2 drops/time

bid). Patients in the treatment group received additional Erlong Zuoci Wan combined with Tongqi San (1 dose/d

bid) based on the treatment of control group. The treatment course was 4 weeks for both groups. The traditional Chinese medicine (TCM) symptom scores and bone conduction threshold under different frequencies were compared between two groups. The AQP-1 and AQP-4 levels in serum were detected in two groups. Result: The TCM symptom scores in treatment group were significantly lower than those in the control group after treatment (P<0.01). The total clinical effective rate was 89.61% in the treatment group

higher than 76.92% in the control group (P<0.05). Bone conduction thresholds under different frequencies (1

2

4

8 kHz) in treatment group were significantly lower than those in control one after treatment (P<0.01). The AQP-1 and AQP-4 levels in serum of treatment group were significantly higher than those of control group after treatment

with statistically significant differences (P<0.01). Conclusion: Erlong Zuoci Wan combined with Tongqi San could significantly improve the clinical symptoms of the patients

decrease bone conduction thresholds

and increase the AQP-1 and AQP-4 levels in serum in the treatment of chronic secretory otitis media with syndrome of deficiency of liver and kidney.